190 related articles for article (PubMed ID: 35151844)
21. Cdc37 as a Co-chaperone to Hsp90.
Prince TL; Lang BJ; Okusha Y; Eguchi T; Calderwood SK
Subcell Biochem; 2023; 101():141-158. PubMed ID: 36520306
[TBL] [Abstract][Full Text] [Related]
22. Cdc37 is a molecular chaperone with specific functions in signal transduction.
Kimura Y; Rutherford SL; Miyata Y; Yahara I; Freeman BC; Yue L; Morimoto RI; Lindquist S
Genes Dev; 1997 Jul; 11(14):1775-85. PubMed ID: 9242486
[TBL] [Abstract][Full Text] [Related]
23. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
[TBL] [Abstract][Full Text] [Related]
24. Serine/Threonine Kinase Unc-51-like Kinase-1 (Ulk1) Phosphorylates the Co-chaperone Cell Division Cycle Protein 37 (Cdc37) and Thereby Disrupts the Stability of Cdc37 Client Proteins.
Li R; Yuan F; Fu W; Zhang L; Zhang N; Wang Y; Ma K; Li X; Wang L; Zhu WG; Zhao Y
J Biol Chem; 2017 Feb; 292(7):2830-2841. PubMed ID: 28073914
[TBL] [Abstract][Full Text] [Related]
25. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
26. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
Li T; Jiang HL; Tong YG; Lu JJ
J Hematol Oncol; 2018 Apr; 11(1):59. PubMed ID: 29699578
[TBL] [Abstract][Full Text] [Related]
28. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
Gray PJ; Stevenson MA; Calderwood SK
Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
Mariño-Enríquez A; Ou WB; Cowley G; Luo B; Jonker AH; Mayeda M; Okamoto M; Eilers G; Czaplinski JT; Sicinska E; Wang Y; Taguchi T; Demetri GD; Root DE; Fletcher JA
Oncogene; 2014 Apr; 33(14):1872-6. PubMed ID: 23584476
[TBL] [Abstract][Full Text] [Related]
30. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
31. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer.
Wang L; Zhang Q; You Q
Med Res Rev; 2022 Jan; 42(1):156-182. PubMed ID: 33846988
[TBL] [Abstract][Full Text] [Related]
32. The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy.
Sreeramulu S; Jonker HR; Langer T; Richter C; Lancaster CR; Schwalbe H
J Biol Chem; 2009 Feb; 284(6):3885-96. PubMed ID: 19073599
[TBL] [Abstract][Full Text] [Related]
33. p17-Modulated Hsp90/Cdc37 Complex Governs Oncolytic Avian Reovirus Replication by Chaperoning p17, Which Promotes Viral Protein Synthesis and Accumulation of Viral Proteins σC and σA in Viral Factories.
Huang WR; Li JY; Wu YY; Liao TL; Nielsen BL; Liu HJ
J Virol; 2022 Mar; 96(6):e0007422. PubMed ID: 35107368
[TBL] [Abstract][Full Text] [Related]
34. Cdc37 goes beyond Hsp90 and kinases.
MacLean M; Picard D
Cell Stress Chaperones; 2003; 8(2):114-9. PubMed ID: 14627196
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
36. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases.
Zhang X; Li S; Li Z; Cheng L; Liu Z; Wang C
Curr Drug Targets; 2022; 23(10):1023-1038. PubMed ID: 35400341
[TBL] [Abstract][Full Text] [Related]
37. Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion.
El Hamidieh A; Grammatikakis N; Patsavoudi E
PLoS One; 2012; 7(8):e42722. PubMed ID: 22912728
[TBL] [Abstract][Full Text] [Related]
38. The Hsp90 co-chaperones Cdc37 and Sti1 interact physically and genetically.
Abbas-Terki T; Briand PA; Donzé O; Picard D
Biol Chem; 2002 Sep; 383(9):1335-42. PubMed ID: 12437126
[TBL] [Abstract][Full Text] [Related]
39. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.
Polier S; Samant RS; Clarke PA; Workman P; Prodromou C; Pearl LH
Nat Chem Biol; 2013 May; 9(5):307-12. PubMed ID: 23502424
[TBL] [Abstract][Full Text] [Related]
40. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics.
Jinwal UK; Trotter JH; Abisambra JF; Koren J; Lawson LY; Vestal GD; O'Leary JC; Johnson AG; Jin Y; Jones JR; Li Q; Weeber EJ; Dickey CA
J Biol Chem; 2011 May; 286(19):16976-83. PubMed ID: 21367866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
